What is the average price target for DEXCOM INC (DC4.DE) stock?
37 analysts have analysed DC4.DE and the average price target is 76.2 EUR. This implies a price increase of 41.1% is expected in the next year compared to the current price of 54.
FRA:DC4 • US2521311074
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for DEXCOM INC (DC4.DE).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2021-08-02 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-07-30 | Oppenheimer | Maintains | Outperform |
| 2021-07-30 | SVB Leerink | Maintains | Outperform |
| 2021-07-30 | Wells Fargo | Maintains | Equal-Weight |
| 2021-07-30 | Raymond James | Maintains | Outperform |
| 2021-07-30 | Canaccord Genuity | Maintains | Buy |
| 2021-07-30 | Piper Sandler | Maintains | Overweight |
| 2021-05-28 | Wells Fargo | Upgrade | Underweight -> Equal-Weight |
| 2021-05-25 | Barclays | Initiate | Overweight |
| 2021-04-30 | Raymond James | Maintains | Outperform |
| 2021-04-30 | Canaccord Genuity | Maintains | Buy |
| 2021-04-30 | Citigroup | Maintains | Buy |
| 2021-04-15 | Atlantic Equities | Initiate | Overweight |
| 2021-02-12 | Raymond James | Maintains | Outperform |
| 2021-02-12 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-02-12 | Citigroup | Maintains | Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 3.622B 24.49% | 4.033B 11.34% | 4.662B 15.60% | 5.336B 14.46% | 5.993B 12.31% | 6.725B 12.21% | 7.565B 12.49% | 8.329B 10.10% | 8.494B 1.98% | 9.469B 11.48% | 10.346B 9.26% | |
| EBITDA YoY % growth | 800.3M 42.66% | 871.2M 8.86% | 1.256B 44.21% | 1.603B 27.59% | 1.906B 18.90% | 2.231B 17.05% | 2.754B 23.44% | 3.007B 9.19% | N/A | N/A | N/A | |
| EBIT YoY % growth | 614.3M 51.64% | 653.5M 6.38% | 1.005B 53.73% | 1.203B 19.75% | 1.457B 21.11% | 1.741B 19.49% | 2.081B 19.53% | 2.401B 15.38% | 2.56B 6.62% | 2.893B 13.01% | 3.203B 10.72% | |
| Operating Margin | 16.96% | 16.20% | 21.55% | 22.54% | 24.31% | 25.89% | 27.51% | 28.83% | 30.14% | 30.55% | 30.96% | |
| EPS YoY % growth | 1.51 73.56% | 1.65 9.27% | 1.86 12.73% | 2.54 36.73% | 3.04 19.53% | 3.64 19.78% | 4.32 18.72% | 4.97 14.91% | N/A | N/A | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.48 49.54% | 0.62 28.30% | 0.69 13.12% | 0.76 67.99% | 0.61 27.36% | 0.73 19.11% | 0.80 16.28% | 0.87 15.70% | 0.81 32.22% | 0.86 16.80% | 0.89 10.59% | 0.92 4.96% |
| Revenue Q2Q % growth | 1.198B 15.64% | 1.323B 14.34% | 1.37B 13.29% | 1.435B 13.93% | 1.355B 13.11% | 1.477B 11.64% | 1.521B 11.02% | 1.597B 11.29% | 1.603B 18.30% | 1.649B 11.65% | 1.682B 10.59% | 1.707B 6.89% |
| EBITDA Q2Q % growth | 320.31M 65.36% | 395.48M 17.84% | 434.04M 1.15% | 469.75M -29.64% | 391.37M 22.18% | 468.24M 18.40% | 503.14M 15.92% | 542.8M 15.55% | 498.6M 27.40% | 534.3M 14.11% | 545.41M 8.40% | 570.52M 5.11% |
| EBIT Q2Q % growth | 222.53M 66.44% | 292.2M 37.44% | 327.62M 35.10% | 360.81M -13.23% | 278.58M 25.19% | 352.11M 20.50% | 382.91M 16.88% | 420.1M 16.43% | 371.93M 33.51% | 395.66M 12.37% | 407.06M 6.31% | 423.3M 0.76% |
All data in USD
37 analysts have analysed DC4.DE and the average price target is 76.2 EUR. This implies a price increase of 41.1% is expected in the next year compared to the current price of 54.
DEXCOM INC (DC4.DE) will report earnings on 2026-04-30.
The consensus EPS estimate for the next earnings of DEXCOM INC (DC4.DE) is 0.48 EUR and the consensus revenue estimate is 1.20B EUR.
The number of analysts covering DEXCOM INC (DC4.DE) is 37.